iTOL-102
Type 1 Diabetes
Key Facts
About iTolerance
iTolerance is a private, preclinical-stage biotech founded in 2020 and based in Miami, Florida. The company's mission is to eliminate the need for chronic immunosuppression in regenerative medicine through its proprietary iTOL-100 immunomodulatory platform, which utilizes a synthetic FasL protein. Its lead programs, iTOL-101 and iTOL-102, aim to cure Type 1 Diabetes using allogeneic cadaveric islets and stem cell-derived islets, respectively, and have shown promising preclinical results in non-human primates. The company is also exploring other applications, including a liver program (iTOL-201) and a potential program for ovarian insufficiency (iTOL-401).
View full company profileAbout Kadimastem
Israeli cell‑therapy biotech developing off‑the‑shelf hESC‑derived treatments for ALS and diabetes.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |